AZRX News and Press, AzurRx BioPharma Inc. From 07/20/20

Private placement resulting in gross cash proceeds of $15.2 million to advance two Phase 2 clinical trials of MS1819 in patients with cystic fibrosis Exchange of $6.9 million principal amount of outstanding promissory notes into private placement strengthens balance sheet NEW YORK, Ju...

NEW YORK, May 07, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX ) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that it has enter...

Received ~$2.52 million in aggregate CIR payments in 2020 CIR to be used to fund on-going MS1819 Phase 2 clinical studies in Europe NEW YORK, May 05, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company spe...

IRB protocol approval provides green-light to initiate trial at U.S. clinical sites NEW YORK, April 30, 2020 (GLOBE NEWSWIRE) --  AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-system...

AzurRx BioPharma ( AZRX +7.3% ) announces that it will conduct its Phase 2 clinical trial, OPTION 2, evaluating lead candidate MS1819 in cystic fibrosis (CF) patients with exocrine pancreatic insufficiency in Therapeutics Development Network (TDN) sites. More news on: AzurRx BioPharma,...

On track to initiate the OPTION 2 trial by the end of Q2 2020 OPTION 2 trial to compare efficacy of standard of care to 2.2 and 4.4 gram doses of MS1819 in enteric capsules Trial completion and top-line data expected in Q1 2021 NEW YORK, April 29, 2020 (GLOBE NEWSWIRE) -- AzurR...

NEW YORK, April 21, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today issued the following le...

NEW YORK, April 20, 2020 (GLOBE NEWSWIRE) -- Argus Research, an independent investment research firm, has launched Equity Research Report coverage on AzurRx BioPharma, Inc.  (NasdaqCM: AZRX) Click here  to view Full Argus Report. Highlights, as conveyed by Argus Analy...

NEW YORK, April 16, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX ) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant  therapies for gastrointestinal diseases, today announced that it h...

BROOKLYN, NY / ACCESSWIRE / April 15, 2020 / AzurRx BioPharma, Inc. (NASDAQ:AZRX), is a clinical stage biopharmaceutical company focused on the development of recombinant proteins for the treatment of gastrointestinal diseases, today announced that it will be presenting at the Planet MicroCa...